Department of Dermatology and Radiotherapy, FMB-UNESP, Botucatu, São Paulo, Brazil.
Department of Pathology, FMB-UNESP, Botucatu, São Paulo, Brazil.
Br J Dermatol. 2018 Nov;179(5):1081-1087. doi: 10.1111/bjd.16824. Epub 2018 Sep 25.
Skin field cancerization (SFC) is a process that occurs in areas of the skin that have undergone genomic alterations induced by ultraviolet radiation. Actinic keratosis (AK) is a sign of its activity.
To evaluate the effectiveness and safety of 0·5% colchicine (COL) cream vs. methyl aminolaevulinate photodynamic therapy (MAL-PDT) in the treatment of AK and SFC.
We conducted a randomized, open, intrasubject controlled trial. A total of 36 participants with 3-10 AKs on each forearm were treated with either COL cream (twice daily for 10 days) or a single session of MAL-PDT and were reassessed after 60 days. The clinical evaluation was performed using AK count, forearm photoageing scale (PAS) and AK degree (AKD). Patients underwent central forearm biopsies and histopathological evaluation by keratinocyte intraepithelial neoplasia (KIN) assessment, epithelial atrophy and immunohistochemistry (p53/Ki67).
Overall, 50% of patients were male. The mean age was 70·9 years (SD 8·6) and phototypes I and II were predominant (89%). Total clearance was observed in six (17%) forearms treated with COL and seven (19%) forearms treated with MAL-PDT (P = 0·76); partial clearance was observed in 44% of forearms in the COL group and 67% of forearms in the MAL-PDT group (P = 0·07). In both COL and MAL-PDT groups, reductions in PAS (-6% vs. -6%) and AKD (-45% vs. -40%) were observed. KIN normalized in 28% of patients treated with MAL-PDT and 20% of those treated with COL. Epithelial atrophy reduced after treatment (P < 0·01). Expression levels of Ki67 and p53 were also assessed. Mild or moderate adverse effects were similar for both groups.
COL 0·5% cream and MAL-PDT are safe and effective for treating SFC.
皮肤光化性角化病(SFC)是一种发生于皮肤的过程,其特征是基因组发生改变,这种改变是由紫外线辐射引起的。光化性角化病(AK)是其活动的标志。
评估 0.5%秋水仙碱(COL)乳膏与甲氨基酮戊酸光动力疗法(MAL-PDT)治疗 AK 和 SFC 的疗效和安全性。
我们进行了一项随机、开放、自身对照试验。共有 36 名参与者,每个前臂有 3-10 个 AK,分别接受 COL 乳膏(每天两次,连用 10 天)或单次 MAL-PDT 治疗,并在 60 天后再次评估。临床评估采用 AK 计数、前臂光老化评分(PAS)和 AK 程度(AKD)进行。患者接受中央前臂活检,并通过角质形成细胞上皮内瘤变(KIN)评估、上皮萎缩和免疫组织化学(p53/Ki67)进行组织病理学评估。
总体而言,50%的患者为男性,平均年龄为 70.9 岁(标准差 8.6),主要为Ⅰ型和Ⅱ型光型(89%)。COL 治疗的 6 只(17%)前臂和 MAL-PDT 治疗的 7 只(19%)前臂观察到完全清除(P = 0.76);COL 组的 44%前臂和 MAL-PDT 组的 67%前臂观察到部分清除(P = 0.07)。在 COL 和 MAL-PDT 两组中,PAS(-6%比-6%)和 AKD(-45%比-40%)均降低。MAL-PDT 治疗的 28%患者和 COL 治疗的 20%患者的 KIN 正常化。治疗后上皮萎缩减少(P < 0.01)。Ki67 和 p53 的表达水平也进行了评估。两组的不良反应均为轻度或中度。
0.5%秋水仙碱乳膏和 MAL-PDT 治疗 SFC 安全有效。